Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Colorcon
Fuji
McKinsey
AstraZeneca
Novartis
Deloitte
Cantor Fitzgerald
Fish and Richardson

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206111

« Back to Dashboard
NDA 206111 describes SYNJARDY, which is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the SYNJARDY profile page.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Summary for NDA: 206111

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Formulation / Manufacturing:see details

Pharmacology for NDA: 206111

Ingredient-typeBiguanides
Mechanism of ActionSodium-Glucose Transporter 2 Inhibitors

Suppliers and Packaging for NDA: 206111

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SYNJARDY
empagliflozin; metformin hydrochloride
TABLET;ORAL 206111 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0159 0597-0159-18 180 TABLET in 1 BOTTLE (0597-0159-18)
SYNJARDY
empagliflozin; metformin hydrochloride
TABLET;ORAL 206111 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0159 0597-0159-60 60 TABLET in 1 BOTTLE (0597-0159-60)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG;500MG
Approval Date:Aug 26, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 2, 2019
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Mar 18, 2019
Regulatory Exclusivity Use:INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN
Regulatory Exclusivity Expiration:Aug 1, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Teva
Merck
Daiichi Sankyo
Argus Health
Harvard Business School
Accenture
Cantor Fitzgerald
Citi
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot